Asia-Pacific Nonalcoholic Steatohepatitis Therapeutics Markets Report 2018-2024 Featuring Key Players - Allergan, Galmed, Genfit, Gilead, Intercept Pharmaceuticals & Zydus

News provided by

Jan 16, 2019, 08:00 ET

DUBLIN, Jan. 16, 2019 /PRNewswire/ --

The "Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering.

The NASH Asia-Pacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%.

NAFLD has become the most common liver disease worldwide. Global prevalence of NAFLD is estimated at 24%; the highest rates are in South America and the Middle East, followed by the US and Europe. NAFLD is also an emerging problem in the Asia-Pacific region, where it is likely to increase in the future. Currently, the prevalence population of Non-Alcoholic Fatty Liver Disease (NAFLD) in Asia is around 25%, like many Western countries. NASH is present in at least 20% of obese adults or children and in at least 5% of those who are overweight. The prevalence of NASH in biopsy-proven NAFLD patients is 63.5% in Asia.

The Asia-Pacific (APAC) Non-Alcoholic Steato-Hepatitis (NASH) market is forecast to grow at a compound annual growth rate (CAGR) of 17.2% from 2017 to 2024. Over the forecast period the prevalence of Non-Alcoholic Steato-Hepatitis (NASH) is expected to increase significantly across the APAC markets, in parallel with the increasing prevalence of associated risk factors such as obesity, type II diabetes (T2D), dyslipidemia and other metabolic conditions.

The rising prevalence population, together with the significant diagnostic advancements using ultrasound and biomarkers, improving health awareness, and increasing affordability and healthcare access, will increase diagnosis and the treatment-receiving population, driving demand and contributing to market growth.

Scope

How will the approval of NASH-specific therapies affect the market?
The NASH market has cheap, generic, off-label drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the NASH market?
How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
How will changes in risk factors such as population age, obesity, type 2 diabetes, NAFLD, metabolic syndrome and lifestyle influence the market?
The pipeline for NASH therapies is quite diverse with a range of molecule types and molecular targets.
Which molecular targets appear most frequently in the pipeline?
How have the late-stage therapies performed in clinical trials?
The level of unmet need in the NASH market is significantly high. Will the pipeline drugs fulfill these unmet needs?
Various drivers and barriers will influence the market over the forecast period.
Licensing deals are the most common form of strategic alliance in NASH, with total deal values ranging from under $10m to over $300m.
How do deal frequency and value compare between target families and molecule types?
What were the terms and conditions of key licensing deals?

Key Topics Covered:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.5.1 Non-invasive Tests
2.6 Disease Classification
2.7 Prognosis
2.8 Co-morbidities
2.9 Treatment Options and Treatment Algorithm
2.9.1 Treatment Options
2.9.2 Treatment Algorithm
2.9.3 Non-pharmacological Treatments

3 Marketed Products
3.1 Overview
3.1.1 Vitamin E
3.1.2 Pentoxifylline
3.1.3 Pioglitazone
3.2 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Selonsertib - Gilead
4.4.2 Elafibrinor - Genfit
4.4.3 Saroglitazar - Zydus
4.4.4 Ocaliva (obeticholic acid) - Intercept Pharmaceuticals
4.4.5 Cenicriviroc - Allergan
4.4.6 Aramchol - Galmed
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Summary of Clinical Trial Metrics

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Rising Awareness and Growing Prevalence of the Disease
7.1.2 Launch of NASH-Specific Therapies
7.1.3 Advancements in Diagnostic Procedures for NASH
7.1.4 Increasing Awareness and Diversified Healthcare Reform
7.2 Barriers
7.2.1 Delayed Diagnosis Due to Complex Pathophysiology
7.2.2 Low Diagnosis and Treatment Rate
7.2.3 High Cost Therapies May Lead to Reimbursement issues

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.2 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.3 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.2 Summary of Multi-scenario Market Forecasts to 2024
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis

Companies Mentioned

Allergan
Galmed
Genfit
Gilead
Intercept Pharmaceuticals
Zydus

For more information about this report visit https://www.researchandmarkets.com/research/52sn67/asiapacific?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets